Answers are grounded in this paper and cite their sources.
This review highlights treatment challenges for endometrial hyperplasia, suggesting a need for better diagnosis and prevention strategies.
As can be seen from the above analysis, despite the fact that endometrial hyperplasia is considered as a risk factor or a precursor to uterine cancer, rather modest attention is paid to this problem, as evidenced by the lack of serious monographs, modern randomized studies, and a relatively small number of original articles. At the same time, many unresolved issues have accumulated that require scientific coverage and further development. This applies to all aspects of the problem, including classification, etiopathogenesis, diagnosis, treatment and prevention. From the above it follows that the continuing interest in endometrial hyperplasia is determined by their tendency to have a long-term recurrent course, the possibility of transformation in some cases into a malignant process (especially atypical endometrial hyperplasia), the absence of specific (pathognomonic) symptoms, as well as the complexity of differential diagnosis and choice of treatment methods. Despite the emergence of new directions in the management of patients with endometrial hyperplastic processes, the treatment of this pathology remains one of the most pressing issues in gynecology, and is still far from a final solution.
No takes yet. Share an insight, caveat, or question.
А. А. Тограмаджян (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: